Signicef® (levoflaxacin 0.5%) eye drops in clinical practice
https://doi.org/10.18008/1816-5095-2012-4-73-77
Abstract
Purpose: to evaluate the effect of levoflaxacin 0.5% eye drops/Signicef® (Promed Exports, India) for prevention of infectious complications following ocular traumas and intraocular surgery as well as infectious disorders treatment.
Methods: In retrospective analysis were included 102 cases of different ophthalmic pathologies following intraocular surgery, i.e., phacoemulsification (27 cases), extracapsular cataract extraction (40 cases), intravitreal injection/IVt of Lucentis (23 cases), abscess/phlegmon drainage (3 cases). Levofloxacin 0.5% (Signicef® Eye Drops) was prescribed according to a scheme before and following ocular surgery for prevention and treatment of infectious complications.
Results: No infectious complications following eye surgery or IVt were observed.
Conclusion: Signicef® use as antibacterial mono-medication is reasonable and sufficient for prevention of post-op infectious
complications as well as ocular traumas and infectious corneal disorders treatment.
About the Author
E. A. Spiridonov
ГБУЗ «Самарская областная клиническая офтальмологическая больница им. Т.И. Ерошевского», Самара
Russian Federation
Russian Federation
References
1. Вохмяков А. В., Околов И. Н. и др. Выбор оптимального антибиотика для профилактики инфекционных осложнений в офтальмохирургии // Клиническая офтальмология. — 2007. — Т. 8, No 1. — С. 37‐40.
2. Воронцова Т. Н., Бржеский В. В., Михайлова М. В. Чувствительность и резистентность к антибактериальным препаратам микрофлоры конъюнктивальной полости у детей //Офтальмология. — 2012. — Т. 9, No 1. — С. 83‐91.
3. Майчук Ю. Ф. Перспектива применения хинолоновых антибиотиков в офтальмологической практике. Актуальные проблемы химиотерапии бактери- альных инфекций. — М., 1991. — С. 408.
4. Barry P., Behrens‐Baumann W., Pleyer U., Seal D. (Ed.). ESCRS guidelines on prevention, investigation and management of postoperative endophthalmitis. Ver- sion 2. — 2007. — 14 p.
5. Holland E. J. New Options for Preventing Infection // Ocular Surgery News. — Sept., 2002. — P. 5‐6.
6. Практическое руководство по антиинфекционной химиотерапии. Под ре- дакцией: Л. С. Страчунского, Ю. Б. Белоусова, С. Н. Козлова. Смоленск: МАК- МАХ, 2007.
7. Nicolau D. P. et al. Antibiotic kinetics and dynamics for the clinician // Med. Clin. North. Am. — 1995. — Vol. 79. — P. 477‐495.
8. Kim SY, Lim JA, Choi JS, et al. Comparison of antibiotic effect and cornea epithe- lial toxicity between levofloxacin and moxifloxacin in vitro // Cornea. — 2007. — Vol. 26. — P. 720‐725.
9. Padma Bezwada, Clark LA, Shneider S. et al. Intrinsic cytotoxic effects of fluoro- quinolones on human corneal keratocytes and endothelial cells // Curr. Med. Res. Opin. 2008. — Vol. 246. — P. 419‐424.
Review
For citations:
Spiridonov E.A. Signicef® (levoflaxacin 0.5%) eye drops in clinical practice. Ophthalmology in Russia. 2012;9(4):73-77. (In Russ.) https://doi.org/10.18008/1816-5095-2012-4-73-77
Views:
4825
Email this article 